1. Catalog
  2. Unmasking MASH and MASLD
Unmasking MASH and MASLD
Create Account
Availability
On-Demand
4 Courses
Cost
$0.00
Credit Offered
2 AMA PRA Category 1 Credits
  • Description
  • Accreditation Information
  • Faculty and Disclosures
  • Privacy Policy
  • Recommended
In recent years, the field of liver disease has undergone a major shift. A global expert consensus in 2023 redefined Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) as Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-Associated Steatohepatitis (MASH). This change reflects a more accurate understanding of the strong links between liver health, metabolic dysfunction, type 2 diabetes, and obesity. A new related category, MetALD (Metabolic dysfunction and Alcohol-associated Steatotic Liver Disease), highlights the need for tailored management strategies for specific patient populations. Why does this matter for you as a clinician? Because MASLD and MASH are highly prevalent in primary care populations, and early recognition and intervention can dramatically improve outcomes. With new nomenclature, evolving guidelines, and emerging therapies, staying current is essential to delivering optimal patient care. Recognizing this, the American Association for the Study of Liver Diseases (AASLD) has identified MASLD/MASH as a top educational priority. This program—developed in collaboration with the American Academy of Physician Associates (AAPA), the American College of Osteopathic Family Physicians (ACOFP), and educational partner AXDEV Global—equips you with the knowledge and tools you need to:

     • Understand the epidemiology and clinical significance of MASLD/MASH
     • Apply best practices in diagnosis and testing, including non-invasive tools and care pathways
     • Stay current on treatment strategies, from lifestyle management to emerging therapies
     • Explore the latest research and how it shapes practice guidelines

This is your opportunity to strengthen your expertise, close critical practice gaps, and better serve patients at risk for liver disease in everyday clinical practice.

This activity is supported by independent educational grants from Boehringer-Ingelheim Pharmaceuticals, Inc. and Novo Nordisk Inc.
Accreditation Statement:

The American Association for the Study of Liver Diseases is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation Statement:

The American Association for the Study of Liver Diseases designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM:

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to .5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.


COPYRIGHT: All faculty in this activity have given their permission for publication ©2025 AASLD.

This online educational activity has been planned in collaboration with AAPA, ACOFP, and AXDEV and in accordance with the AASLD Financial Disclosure Policy and ACCME Standards for the Integrity and Independence for Accredited Continuing Education.
As an accredited provider, AASLD must collect information from all planners, faculty and others in the planning and control of continuing medical education (CME) activities to disclose all of their financial relationships with ineligible companies within the prior 24 months. Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. There is no minimum financial threshold; individuals must disclose all financial relationships, regardless of the amount, in ineligible companies. Individuals must disclose financial relationships with ineligible companies regardless of their view of the relevance of the relationship to the education. The American Association for the Study of Liver Diseases (AASLD) has implemented a system to resolve conflicts of interest for each CME activity to help ensure content is objective, fair balanced, independent, and free of commercial bias. Conflicts, if any, are resolved through one or more processes. All relevant conflicts pertaining to this activity have been mitigated.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of AASLD. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. The AXDEV MASLD Multiprofessional Program Planning Committee has disclosed the following financial relationships. All relevant conflicts of interest have been mitigated:

Robert Fontana, MD, FAASLD
Scientific Consultant/Advisor: CymaBay, Sanofi
Consulting: MasterSwitch, Metsera, Roche Pharmaceuticals
Research Grants: Bristol Myers-Squibb, Gilead, AbbVie, Fractyl Health, Kezar Pharmaceuticals, MiroMatrix, Takeda

Hilary Lois, DO
Nothing to Disclose

Cara Orr, PA-C
Scientific Consultant/Advisor: Orderly Meds

Sarah Repking, RN, MSN, ACNP- BC
Nothing to Disclose

Niharika Samala, MBBS
Scientific Consultant/Advisor: MASH Net
Research Grants: Petauri
Speaker’s Bureau: Health Pro Match

All staff have nothing to disclose:

AAPA:
Leah Eberhardt
Daniel Pace
Eric Peterson

AASLD:
Steven Folstein
Laura Shelters

ACOFP:
Lyndsey Aspaas
Steve Legault
Paige Zelinsky

AXDEV:
Randa Dalle
Patrice Lazure
Deborah Talamonti

Powered By